Molecule is not just a “version” of Kickstarter for biology. More definitively, it is a conglomerate of Decentralized Autonomous Organizations
Going to the doctor’s office today does not always bring the word “care” to mind. Visits are often rushed, with endless phone calls and effort to access information online bookending an already de-personalized process. Transferring information across healthcare providers is a herculean task, one that is only really matched by the effort required to get the necessary referrals from one doctor for another.
For Paul Kohlhaas and Vincent Weisser at Molecule, these are all just symptoms of a broader problem: the extent to which profit has become an overly — if not— deciding factor in medicine. With a high-level goal to cure diseases, they’re most interested in the question of how to fix a broken market, starting with addressing a lack of data liquidity. Ahead of speaking at, they shared a few key insights about their big-picture thinking.
“Our thesis is that the best way to fix these problems is to involve patients as a platform to drive and fund research. So we think of Molecule as a Kickstarter-type marketplace for translational work for these communities,” explains Weisser, Chief Ecosystem Development Officer. In other words, to fix problems in the doctor’s office, Molecule wants to put patients in the driver’s seat in terms of the very data that enables them to be treated at all.
Molecule is not just a “version” of Kickstarter for biology. More definitively, it is a conglomerate of that is built around a cryptocurrency protocol that decentralizes funding and intellectual property ownership. By using this protocol and its instruments — specifically, IP-NFTs or intellectual property non-fungible tokens — to tokenize sponsored research agreements, Molecule aims to make these aspects of the research process more transferrable and liquid.
Kohlhaas, as Co-Founder and CEO of Molecule, cites his background in economics and interest in systems thinking and design as foundational to his understanding of problems stemming from centralizing authorities in terms of funding, replication, competition, and communication. “Incentives for medicines to be brought to market are not to cure but to treat people and build sustainable business models around medicine,” he argues.
日本 最新ニュース, 日本 見出し
Similar News:他のニュース ソースから収集した、これに似たニュース記事を読むこともできます。
Stellantis Halts Construction Of Canada Battery Plant Over IncentivesConstruction on the Windsor, Ontario battery module site has stopped, with Stellantis accusing the Canadian government of not keeping its side of the bargain.
続きを読む »
The Stars Come Out for Texas Film and Video Game IncentivesIn a new commercial, some of the most famous Texans to have ever graced the silver screen promote the benefits of the Texas Moving Image Industry Incentive Program.
続きを読む »
Malta Attracting Big-Budget Shoots With Aggressive Incentives and Adaptable LocationsLocated in the Mediterranean Sea, 50 miles south of Sicily and 176 miles east of Tunisia, the island Republic of Malta has a long history as a filming location stretching back to the 1925 silent “S…
続きを読む »
Bidding wars: Police agencies dangle incentives to attract new recruits, transfersFrom signing bonuses to child-care and rent subsidies, law enforcement agencies are opening their wallets to bolster depleted staffs with new officers.
続きを読む »
San Diego officer vacancies prompt creative incentives by Chief, union -SAN DIEGO (KUSI) – The San Diego Police Department is facing its biggest officer shortage in over 15 years. In honor of National Police Week, local law enforcement have attempted to spread awareness about the issue. Law enforcement leaders have been forced to get creative to attract candidates, including offering childcare services and hiring bonuses. Still, San Diego’s starting wages...
続きを読む »